GRI Bio to Present Phase 2a Data on IPF Therapy at IPF Summit

Event summary

GRI Bio's CEO and CSO to present at the 10th IPF Summit on September 30 and October 1, 2026.
Presentations will focus on immune modulation and Phase 2a development insights for IPF therapy GRI-0621.
GRI-0621 is an oral RARβ/γ-selective agonist targeting idiopathic pulmonary fibrosis (IPF).
Company highlights encouraging Phase 2a findings across lung function, biomarkers, and tolerability.

The big picture

GRI Bio's presentation at the IPF Summit underscores the growing focus on immune modulation in fibrotic diseases. The company's Phase 2a data could position GRI-0621 as a potential oral alternative in the IPF space, which currently lacks curative options. Success here would validate GRI Bio's approach to targeting underlying biological drivers of fibrosis, a strategy increasingly prioritized by investors and regulators.

What we're watching

Clinical Validation: How Phase 2a data will influence the design and timing of Phase 2b trials for GRI-0621.
Competitive Positioning: Whether GRI Bio can differentiate GRI-0621 in the IPF market against existing and emerging therapies.
Funding Requirements: The pace at which GRI Bio secures additional capital to support late-stage development of GRI-0621.